About Us: Directors and Management
Dr Andrew Muir, Non-Executive Director
Andrew started his career with ICI and Zeneca, including a secondment to the University of Southern Mississippi in the USA. He was a research manager at Biocompatibles, with responsibility for their ophthalmic patent portfolio and Vice President of Global Technology at the US medical device start up Sterilox Technologies, before joining the National Endowment of Science, Technology and the Arts (NESTA) as investment manager for life sciences.
He is currently Investment Director for the Rainbow Seed Fund, an early stage fund dedicated to the commercialisation of over £1bn of publicly funded research in the UK. Andrew has a D.Phil and MA in Chemistry from Oxford University. He is a non-executive director of Warwick Effect Polymers and non-executive Chairman of Chameleon Biosurfaces Ltd.
Professor Michael Wakelam, Non-Executive Director
Michael Wakelam has been the Director and Chief Executive of the Babraham Institute since January 2007 and a Director of Babraham Biosciences Technologies. He was previously the Professor of Molecular Pharmacology at the CRUK Institute for Cancer Studies, Birmingham University where he now holds an honorary Chair. His research focuses upon cell signalling, in particular the roles and regulation of lipid signalling pathways in normal and diseased cells, much of the work is focussed upon identifying novel therapeutic targets and disease biomarkers. In addition to core BBSRC funding his work is supported by programme grants from the MRC and CR-UK.
Professor Wakelam is a member of the BBSRC Strategy Board and the Wellcome Trust Expert Review Group for Translation Awards. He was previously Chair of the Molecular and Cellular Medicine Board of the MRC and a member of MRC Council. He was also Chair of the Signal Transduction Theme Panel and a member of the Council of the Biochemical Society.